GlassScriptPhysician profile
Amy K Richardson
NPI 1285672014
$1,722.04
in general payments reported to CMS, 2019-2025
30 companies · $473 in 2025
The $473 reported for 2025 was more than what 79% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $284 · 2020: $49.68 · 2022: $90.55 · 2023: $483 · 2024: $343 · 2025: $473.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,298.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,298.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $188.55 | 2023-2025 | Veozah, Myrbetriq |
| Pfizer INC. | $138.17 | 2023-2025 | |
| Biogen, INC. | $130.86 | 2025 | Zurzuvae |
| Aspira Women'S Health INC | $126.25 | 2022-2023 | Ova1 |
| Boston Scientific Corporation | $122.05 | 2019-2023 | Watchman Access System |
| Channel Medsystems, INC. | $120.01 | 2023-2024 | |
| Hologic Sales and Service, LLC | $113.44 | 2023-2025 | Acessa Provu System, Novasure, Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Abbott Laboratories | $98.96 | 2019-2023 | Nc Trek Neo |
| Abbvie INC. | $95.42 | 2019-2023 | |
| Sumitomo Pharma America, INC. | $61.15 | 2023-2025 | Myfembree |
| Coopersurgical, INC. | $56.66 | 2024-2025 | Paragard T 380a |
| Vantive US Healthcare LLC | $47.14 | 2025 | Renal - Acute |
| Allergan, INC. | $39.75 | 2019 | |
| Novo Nordisk INC | $35.17 | 2024 | Wegovy |
| Mayne Pharma Commercial LLC | $34.95 | 2023 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $34.93 | 2024-2025 | |
| Therapeuticsmd, INC. | $33.54 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $30.37 | 2023 | Gardasil 9 |
| Shield Therapeutics INC | $29.10 | 2025 | |
| Duchesnay USA Incorporated | $24.20 | 2019 | |
| Gynesonics, INC. | $20.44 | 2024 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Agile Therapeutics, INC. | $18.45 | 2023 | Twirla |
| Endo Pharmaceuticals INC. | $18.39 | 2024 | Xiaflex |
| Myovant Sciences INC. | $18.17 | 2022 | |
| Millicent US INC | $16.53 | 2025 | Intrarosa |
| Exeltis, USA INC. | $15.20 | 2023 | Slynd |
| W. L. Gore & Associates, INC. | $15.15 | 2023 | Gore Cardioform Septal Occluder |
| Exact Sciences Corporation | $13.67 | 2023 | Cologuard Collection Kit |
| Astellas Pharma Global Development | $13.27 | 2024 | Vyloy |
| Siemens Medical Solutions USA, INC. | $12.10 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Richardson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.